Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Tuberculosis
Would you consider adding azithromycin to standard antituberculosis treatment to reduce inflammation and tissue damage in patients with pulmonary tuberculosis?
Dekkers BG, et al., PMID 39932906
Related Questions
Would you consider using thalidomide for treating HIV-associated tuberculosis-IRIS in adult patients who have poor response or intolerance to corticosteroid therapy?
How would you approach using pyrazinamide to treat active pulmonary tuberculosis in an East Asian patient with a history of gout, with a uric acid level of 9.5 mg/dl who is not on allopurinol?
Under what circumstances would you choose the 1-month 1HP treatment over a 3-4 month regimen for latent TB?
Do you routinely treat pregnant patients for latent tuberculosis or delay treatment until 2-3 months post-partum?
What is your preferred method for latent tuberculosis screening prior to outpatient hemodialysis initiation for a patient with new dialysis requirements?
How do you manage increasing EBV viremia of 15,000 copies in a seropositive heart transplant recipient with transplant performed 15 years ago in a patient who is otherwise asymptomatic?
How would you manage an early postoperative spinal implant infection when intraoperative cultures while on antibiotics are negative, no frank purulence or other evidence of infection is observed during washout, but there were fascial defects and fluid tracking down to the hardware?
How would you manage a frail but functioning elderly patient with extensive thoracolumbar spinal fusions 4-5 years ago now presenting with copious purulent drainage from L2-L4 whose MRI shows no osteomyelitis or abscess, and who has mild pain but no systemic signs or symptoms of illness?
Do you use daptomycin interchangeably with staphylococcal beta-lactams for ease of dosing on discharge for patients with serious MSSA infections (endocarditis, bacteremias, etc)?
Would you recommend switching from an integrase strand transfer inhibitor-based regimen to a different antiretroviral regimen, or would you instead add weight loss medications for a person with HIV experiencing weight gain that has not improved with lifestyle changes?
